ATH-1020 by Athira Pharma for Depression: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ATH-1020 overview

ATH-1020 is under development for the treatment of neuropsychiatric indications including anxiety disorders, depression and schizophrenia, neuropathic pain and neurodegenerative diseases. It is administered by the oral route formulated as a capsule. It acts by targeting hepatocyte growth factor and hepatocyte growth factor receptor (MET).

For a complete picture of ATH-1020’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.